Trials / Sponsors / ArriVent BioPharma, Inc.
ArriVent BioPharma, Inc.
Industry · 4 registered clinical trials — 2 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor a Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer | Phase 3 | 2025-12-17 |
| Recruiting | A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer | Phase 1 | 2025-07-25 |
| Active Not Recruiting | Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations | Phase 3 | 2023-06-01 |
| Active Not Recruiting | Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activat Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer | Phase 1 | 2022-06-30 |